Annette Tognela

Annette Tognela

Auto-generated profile, based on publicly available information

Annette Tognela

Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
PGPeter Grimison
Peter Grimison
AMAntony Mersiades
Antony Mersiades
AKAdrienne Kirby
Adrienne Kirby
ATAnnette Tognela
Annette Tognela
IOIan Olver
Ian Olver
MSMartin Stockler
Martin Stockler
PURPOSE: The aim of this randomized, placebo-controlled, two-stage, phase II/III trial was to determine the efficacy of an oral cannabis extract in adults with refractory nausea and/or vomiting during moderately or highly emetogenic, intravenous chemotherapy despite guideline-consistent antiemetic prophylaxis. Here, we report results of the prespecified combined analysis including the initial phase II and subsequent phase III components. PATIENTS AND METHODS: Study treatment consisted of oral capsules containing either tetrahydrocannabinol 2.5 mg plus cannabidiol 2.5 mg capsules (THC:CBD) or matching placebo, taken three times a day from days –1 to 5, in addition to guideline-consistent antiemetics. The primary measure of effect was the difference in the proportions of participants with no vomiting or retching and no use of rescue medications (a complete response) during hours 0-120 after the first cycle of chemotherapy on study (cycle A). RESULTS: We recruited 147 evaluable of a planned 250 participants from 2016 to 2022. Background antiemetic prophylaxis included a corticosteroid and 5-hydroxytryptamine antagonist in 97%, a neurokinin-1 antagonist in 80%, and olanzapine in 10%. THC:CBD compared with placebo improved the complete response rate from 8% to 24% (absolute difference 16%, 95% CI, 4 to 28, P = .01), with similar effects for absence of significant nausea, use of rescue medications, daily vomits, and the nausea scale on the Functional Living Index—Emesis quality-of-life questionnaire. More frequent bothersome adverse events of special interest included sedation (18% v 7%), dizziness (10% v 0%), and transient anxiety (4% v 1%). There were no serious adverse events attributed to THC:CBD. CONCLUSION: THC:CBD is an effective adjunct for chemotherapy-induced nausea and vomiting despite standard antiemetic prophylaxis, but was associated with additional adverse events. Drug availability, cultural attitudes, legal status, and preferences may affect implementation. Future analyses will evaluate the cost-effectiveness of THC:CBD.

6 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DDDaphne Day
Daphne Day
LGLisa Grech
Lisa Grech
MNMike Nguyen
Mike Nguyen
NBNathan Bain
Nathan Bain
AKAlastair Kwok
Alastair Kwok
MIMSVACCS investigators
MSVACCS investigators
Objective To examine vaccine uptake, hesitancy and explanatory factors amongst people with serious and/or chronic health conditions, including the impact of underlying disease on attitudes to vaccination. Design Cross-sectional survey. Setting Ten Australian health services. Participants 4683 patients (3560 cancer, 842 diabetes and 281 multiple sclerosis) receiving care at the health services participated in the 42-item survey, between June 30 to October 5, 2021. Main outcome measures Sociodemographic and disease-related characteristics, COVID-19 vaccine uptake, and the scores of three validated scales which measured vaccine hesitancy and vaccine-related beliefs generally and specific to the participants’ disease, including the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale and the Disease Influenced Vaccine Acceptance Scale. Multivariable logistic regression was used to determine the associations between scale scores and vaccine uptake. Results Of all participants, 81.5% reported having at least one COVID-19 vaccine. Unvaccinated status was associated with younger age, female sex, lower education and income, English as a second language, and residence in regional areas (all p<0.05). Unvaccinated participants were more likely to report greater vaccine hesitancy and more negative perceptions toward vaccines (all p<0.05). Disease-related vaccine concerns were associated with unvaccinated status and hesitancy, including greater complacency about COVID-19 infection, and concerns relating to vaccine efficacy and impact on their disease and/or treatment (all p<0.05). Conclusions Disease-specific concerns impact COVID-19 vaccine-related behaviours and beliefs in people with serious and/or chronic health conditions. This highlights the need to develop targeted strategies and education about COVID-19 vaccination to support medically vulnerable populations and health professionals. Trial registration ACTRN12621001467820

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ATAnnette Tognela
Annette Tognela
DEDavid Espinoza
David Espinoza
ADAndrew Davidson
Andrew Davidson
MCMatthew Chan
Matthew Chan
BHBrett Gordon Maxwell Hughes
Brett Gordon Maxwell Hughes
O(on behalf of the Australasian Lung cancer Trials Group (ALTG)
on behalf of the Australasian Lung cancer Trials Group (ALTG)
9074 Background: We have proposed that best, worst, and typical scenarios for survival, based on simple multiples of an individual’s expected survival time (EST) estimated by their oncologist, are a useful way of formulating and explaining prognosis in advanced cancer. The aim of this study was to determine the accuracy and prognostic significance of such estimates in a multicenter, randomized trial. Methods: Oncologists recorded their estimate of the ‘expected survival time’ at baseline in each of 372 patients recruited in the NITRO trial. We hypothesized that oncologists’ estimates of EST would be well-calibrated (~50% of patients living longer or shorter than EST) and imprecise ( < 33% living within 0.75 to 1.33 time their EST), but provide accurate scenarios for survival time (~10% dying within a quarter of their EST, 10% living longer than 3 times their EST, and 50% living for half to double their EST). We also hypothesized that oncologists’ estimates of EST would be independently significant predictors of survival in a multivariable Cox model adjusting for traditional prognostic factors selected in the first 250 participants recruited, and validated in the remaining 122. Results: Oncologists’ estimates of EST were well calibrated (51% of patients lived longer than their EST), but imprecise (24% lived within 0.75 to 1.33 times their EST). Scenarios based on the oncologists’ estimates were accurate: 9% of patients died within ¼ of their EST, 12% lived longer than 3 times their EST, and 53% lived from half to double their EST. Oncologists’ estimates of EST were independently significant predictors of overall survival (HR 0.92, 95% CI 0.88 to 0.96, p < 0.001) in Cox models accounting for ECOG performance status, liver metastases, neutrophil to lymphocyte ratio, and anaemia. Conclusions: Oncologists’ estimates of EST were well calibrated, imprecise, and independently significant predictors of survival above and beyond traditional prognostic factors. Best, worst and typical scenarios for survival based on EST were remarkably accurate, and are a good solution to the problem of estimating prognosis in advanced cancer. Clinical trial information: ACTRN12608000588392.

10 July 2022 in medRxiv
Verified
Preprint
Open access
PDF file
NBN. Bain
N. Bain
MNMike Nguyen
Mike Nguyen
LGLisa Grech
Lisa Grech
DDDaphne Day
Daphne Day
AMAmelia McCartney
Amelia McCartney
TIthe CANcer patients’ perspectives on coronavirus VACCination Survey(CANVACCS) investigators
the CANcer patients’ perspectives on coronavirus VACCination Survey(CANVACCS) investigators
Background: Vaccination is the cornerstone of the global public health response to the COVID-19 pandemic. Excess morbidity and mortality of COVID-19 infection is seen in people with cancer. COVID-19 vaccine hesitancy has been observed in this medically vulnerable population, although associated attitudes and beliefs remain poorly understood. Patients and Methods: An online cross-sectional survey of people with solid organ cancers was conducted through nine health services across Australia. Demographics, cancer-related characteristics, and vaccine uptake were collected. Perceptions and beliefs regarding COVID-19 vaccination were assessed using the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale, and the Disease Influenced Vaccine Acceptance Scale-6. Results: Between June and October 2021, 2691 people with solid organ cancers completed the survey. Median age was 62.5 years ( SD =11.8; range 19-95), 40.9% were male, 71.3% lived in metropolitan areas, and 90.3% spoke English as their first language. The commonest cancer diagnoses were breast (36.6%), genitourinary (18.6%) and gastrointestinal (18.3%); 59.2% had localized disease and 56.0% were receiving anti-cancer therapy. Most participants (79.7%) had at least one COVID-19 vaccine dose. Vaccine uptake was higher in people who were older, male, metropolitan, spoke English as a first language, and had a cancer diagnosis for more than six months. Vaccine hesitancy was higher in people who were younger, female, spoke English as a non-dominant language and lived in a regional location, and lower in people with genitourinary cancer. Vaccinated respondents were more concerned about being infected with COVID-19 and less concerned about vaccine safety and efficacy. Conclusions: People with cancer have concerns about acquiring COVID-19, which they balance against vaccine-related concerns about the potential impact on their disease progress and/or treatment. Detailed exploration of concerns in cancer patients provides valuable insights, both for discussions with individual patients and public health messaging for this vulnerable population.

5 November 2018 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MKMustafa Khasraw
Mustafa Khasraw
KMKerrie McDonald
Kerrie McDonald
SYSonia Yip
Sonia Yip
RVRoel Verhaak
Roel Verhaak
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
ZLZarnie Lwin
Zarnie Lwin
An increase of mutations as we age is well documented in GBM and in cancer in general. Elderly patients with GBM may have higher mutational burden and may be more likely to respond to immunotherapies. NUTMEG is a randomised Phase II study comparing post radiation NivolUmab and TMZ versus TMZ alone in Elderly patients with newly diagnosed GBM. 102 patients will be randomized in a 2:1 allocation to receive short course RT (40Gy/15 daily fractions) and TMZ 75mg/m2) followed by 6 cycles of adjuvant TMZ (150-200mg/m2 days (D) 1–5 q28 days) with Nivolumab (240 mg D1, 15 q28 days for cycles (C) (1–4; 480 mg D1 Q 28 days for C5-6) versus 6 cycles of adjuvant TMZ (150-200mg/m2 D1-5 q28) alone. The study is stratified for ECOG performance status, age (< 70 vs 70), MGMT methylation and extent of resection. An independent safety monitoring committee is overseeing the trial and will review safety data for the first 10 patients treated on the experimental arm (TMZ + Nivolumab). The primary endpoint is Overall Survival (OS). Secondary endpoints include: 6 month Progression Free Survival, adverse events (AEs) and immune AEs, Quality of life, neurological function (NANO Scale), and correlation of modified RANO and iRANO in the experimental arm. Translational research endpoints include correlation of clinical endpoints with mutational burden, comprehensive immune characteristics and novel MRI sequences including pH-weighted MRIs. The expected proportion of patients alive at 24 months is predicted to be 15.7%. A hazard ratio of more than 0.69 in favour of the Nivolumab + TMZ arm will be considered sufficient to warrant further investigation including converting this study into a phase III trial. PROGRESS: At 3 June 2018, 6/18 study sites are open in Australia with 5 patients randomized. ACTRN12617000267358.

13 September 2022 in Annals of Oncology
Verified
Journal Article
Closed access
MNMike Nguyen
Mike Nguyen
NBN.T. Bain
N.T. Bain
LGLisa Grech
Lisa Grech
AKAlastair Kwok
Alastair Kwok
NHN. Hamad
N. Hamad
Eva SegelovEva Segelov
Eva Segelov